Dachaigh › Scleroderma › Massachusetts
Sgrùdaidhean clionaigeach Scleroderma ann an Massachusetts
Tha 7 sgrùdaidhean airson Scleroderma a’ lorg phàirtichean aig làraichean ann an Massachusetts.
Bailtean ann an Massachusetts
Teacsa sgrùdaidh oifigeil (Beurla)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT03816345A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Massachusetts General Hospital, Boston
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT07497087A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Boston Medical Center, Boston
A’ fastadhÌre 1
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Massachusetts General Hospital, Boston
- Boston University (BU), Boston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT06195072Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
- Shapiro Outpatient Rheumatology Clinic at Boston Medical Center, Boston
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Iuch 2026 · NCT07090226A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Brigham And Womens Hospital, Boston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Iuch 2026 · NCT07115745Open Label Treprostinil Raynaud's Study
- Brigham and Women's Hospital, Boston
- Brigham and Women's Hospital, Boston
A’ fastadhÌre 4
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Màrt 2026 · NCT07112183Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.